Development
Ocular Therapeutix, Inc.
OCUL
$8.15
-$0.18-2.16%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -13.65% | -12.99% | -179.16% | -299.77% | -984.05% |
| Total Depreciation and Amortization | 41.44% | 14.99% | -6.07% | -12.74% | -12.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 87.16% | 190.40% | 182.91% | 155.75% | 113.63% |
| Change in Net Operating Assets | -649.37% | -221.96% | -531.06% | 151.17% | 146.50% |
| Cash from Operations | -17.84% | -12.01% | -21.81% | 8.71% | 9.07% |
| Capital Expenditure | -63.85% | -254.19% | -395.41% | -419.66% | -211.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -63.85% | -254.19% | -395.41% | -419.66% | -211.14% |
| Total Debt Issued | -- | -- | -- | -46.27% | -- |
| Total Debt Repaid | -- | -- | -- | 4.03% | -- |
| Issuance of Common Stock | 8,061.14% | 558.51% | 436.33% | -43.95% | -59.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 11,580.06% | 3,635.18% | 436.33% | -66.13% | -49.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 251.15% | 82.17% | -18.51% | -3.80% | 3.18% |